Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics cash
Cash and short-term investments held at the end of each period.
Spyre Therapeutics's cash was $1.10B at Jun 30, 2026. For fiscal 2025 it was $756.50M, up 25.4% from the year before. Over ten years it grew 36.8% a year on average. The highest annual figure on record is $756.50M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $756.50M | +25.4% |
| FY2024 | Dec 31, 2024 | $603.10M | +77.7% |
| FY2023 | Dec 31, 2023 | $339.30M | +492.5% |
| FY2022 | Dec 31, 2022 | $57.26M | -39.7% |
| FY2021 | Dec 31, 2021 | $94.97M | -35.9% |
| FY2020 | Dec 31, 2020 | $148.12M | +105.9% |
| FY2019 | Dec 31, 2019 | $71.95M | -3.4% |
| FY2018 | Dec 31, 2018 | $74.50M | +48.1% |
| FY2017 | Dec 31, 2017 | $50.30M | -20.8% |
| FY2016 | Dec 31, 2016 | $63.50M | +92.1% |
| FY2015 | Dec 31, 2015 | $33.06M | +1163.8% |
| FY2014 | Dec 31, 2014 | $2.62M | -43.1% |
| FY2013 | Dec 31, 2013 | $4.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.10B | +108.9% |
| Q1 FY2026 | Mar 31, 2026 | $741.50M | +31.3% |
| Q4 FY2025 | Dec 31, 2025 | $756.50M | +25.4% |
| Q3 FY2025 | Sep 30, 2025 | $486.20M | +17.4% |
| Q2 FY2025 | Jun 30, 2025 | $526.58M | +23.5% |
| Q1 FY2025 | Mar 31, 2025 | $564.82M | +16.5% |
| Q4 FY2024 | Dec 31, 2024 | $603.10M | +77.7% |
| Q3 FY2024 | Sep 30, 2024 | $414.23M | +103.5% |
| Q2 FY2024 | Jun 30, 2024 | $426.30M | +81.1% |
| Q1 FY2024 | Mar 31, 2024 | $485.00M | +1119.0% |
| Q4 FY2023 | Dec 31, 2023 | $339.30M | +492.5% |
| Q3 FY2023 | Sep 30, 2023 | $203.60M | +170.7% |
| Q2 FY2023 | Jun 30, 2023 | $235.36M | +165.8% |
| Q1 FY2023 | Mar 31, 2023 | $39.79M | -40.4% |
| Q4 FY2022 | Dec 31, 2022 | $57.26M | -39.7% |
| Q3 FY2022 | Sep 30, 2022 | $75.21M | -33.1% |
| Q2 FY2022 | Jun 30, 2022 | $88.55M | -31.1% |
| Q1 FY2022 | Mar 31, 2022 | $66.73M | -47.3% |
| Q4 FY2021 | Dec 31, 2021 | $94.97M | -35.9% |
| Q3 FY2021 | Sep 30, 2021 | $112.43M | -19.7% |
| Q2 FY2021 | Jun 30, 2021 | $128.58M | -18.5% |
| Q1 FY2021 | Mar 31, 2021 | $126.66M | +158.5% |
| Q4 FY2020 | Dec 31, 2020 | $148.12M | +105.9% |
| Q3 FY2020 | Sep 30, 2020 | $139.98M | +57.8% |
| Q2 FY2020 | Jun 30, 2020 | $157.73M | +49.4% |
| Q1 FY2020 | Mar 31, 2020 | $48.99M | -60.4% |
| Q4 FY2019 | Dec 31, 2019 | $71.95M | -3.4% |
| Q3 FY2019 | Sep 30, 2019 | $88.70M | +37.1% |
| Q2 FY2019 | Jun 30, 2019 | $105.54M | +46.2% |
| Q1 FY2019 | Mar 31, 2019 | $123.70M | +184.4% |
| Q4 FY2018 | Dec 31, 2018 | $74.50M | +48.1% |
| Q3 FY2018 | Sep 30, 2018 | $64.70M | +16.2% |
| Q2 FY2018 | Jun 30, 2018 | $72.20M | +13.9% |
| Q1 FY2018 | Mar 31, 2018 | $43.50M | -24.9% |
| Q4 FY2017 | Dec 31, 2017 | $50.30M | -20.8% |
| Q3 FY2017 | Sep 30, 2017 | $55.70M | -18.1% |
| Q2 FY2017 | Jun 30, 2017 | $63.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $57.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.50M | – |
| Q3 FY2016 | Sep 30, 2016 | $68.00M | – |
See a number that looks wrong?